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Overview of Law and Policy Challenges
Bartha Maria Knoppers*
I will set the context for the next day and a half for the three
particular topics that we will address. However, first I will take
you through four phenomena that are affecting how population
health, how pharmacogenomics and the Haplotype Map will be
received, and how policies will or will not be crafted.
The four phenomena, drawn from experience over the last
fifteen years, may be described as (1) reductionism, (2)
overgeneralization, (3) exceptionalism, and (4) commercialization.
These four phenomena affect how policy is made and how the
public perceives genomic advances.
The most troubling of these phenomena is the first, the
phenomenon of reductionism, which I refer to as "genes are us."
This phenomenon has been driven by the perception that you are
your genes, and you are fatally determined and predisposed by
your genetic code. In the United States, this perception has led
lawmakers to adopt genetics-specific laws-for example, to
prohibit employer and insurer discrimination based upon genetic
information. The premise for this legislation is that additional
statutory protection is necessary because genetic information is
different from other medical information-i.e., genetic information
will not be understood, and you will be perceived by employers
and insurers as already ill based upon your genes.
Reductionism is not particular to the U.S., where there is no
universal health care system. European countries also have been
adopting this "genes are us" reductionist or determinist approach,
because they see life insurance as a social good.' Life insurance is
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a requisite to buy a car, have a mortgage, or take out a loan.2
Many Europeans are concerned that, should insurers get hold of
genetic information, they probably will misinterpret it and use it
against the candidate by driving up fees or put life insurance totally
out of citizens' hands. The resulting legislative approach
undermines the potential of genetics, and actually serves to
exacerbate possible discrimination rather than normalizing genetic
information as medical information that may be highly sensitive.
The second phenomenon is overgeneralization, and this is what
I call the "spill-over effect"-the view that nature is immutable,
nature is static, and genes should not be touched. And so, coming
from a totally different field, nothing to do with genetic diseases,
are genetically modified organisms, or GMOs. Now, this country
in particular has been spared some of the ravages of the movement
against GMOs that is playing itself out in Europe, but we are
beginning to see the effects in Canada with calls for labelling on
anything that has been genetically modified.3 Well, I would
predict that, if you are really going to be honest in this labelling,
you are going to find it extremely difficult if not impossible to
implement. In Europe, where they have adopted this approach,
they have not been able to put the labelling into effect yet. The
Europeans are discovering that virtually everything, somewhere
along the line, has been genetically modified. Nevertheless, this
view of nature as static, as immutable, and the idea that companies,
such as Monsanto, are harming the environment, harming genes,
harming people, has further diminished public trust in the future of
genetics.
The third phenomenon, exceptionalism, is my favorite because
this is how I get through customs. When people ask me, "What do
you do? Why are you going down to the United States?" if I say,
2. Bartha Maria Knoppers et al., A Comparative International Overview,
in Genetics and Life Insurance, Medical Underwriting and Social Policy (Mark
A. Rothstein ed., 2004).
3. See, e.g., Canadian General Standards Board, Voluntary Labeling and
Advertising of Foods That Are and Are Not Products of Genetic Engineering,
http://www.pwgsc.gc.ca/cgsb/032_025/standard-e.html; Canadian Food
Inpection Agency, http://www.inspection.gc.ca/english/corpaffr/newcom/2004/
20040415e.shtml; The Campaign to Label Genetically Engineered Foods,
http://www.thecampaign.org/canada/index.php.
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"Biotechnology and ethics," their eyes sort of get bigger and they
say, "Well, what is that?" So now I just say, "Well, you know,
Dolly .... , Everyone knows Dolly. Dolly, the icon, not only
gets me through customs, but also has served, if you like, as a
target for cloning technology and has helped to inspire an
international movement to promote a ban on, and adopt an
international convention against, human reproductive cloning. 5
Now, this is one of the areas where we do find, in spite of
different norms, ethics, cultures, and worldviews around the globe,
quite a lot of consensus. But the inability to adopt a United
Nation's convention over the last three years is attributable to
usurpation of Dolly in the political domain. Dolly has been used in
political rhetoric to say that, in addition to banning human
reproductive cloning, we should ban all forms of cloning,
including therapeutic cloning which uses stem cells from pre-
embryos.6 The net effect of "Dolly" is laws and protection
mechanisms crafted for anything in the area of gene therapy or
research and, like the previous phenomenon, technology becomes
"genetic" and suspect. Consequently, the possibility of creating
the first international instrument in the area of biotechnology, an
instrument that will manage to achieve some consensus, looks
quite dim, at least over the next few years.
The fourth phenomenon is commercialization. I have been
interacting with geneticists for about fifteen years now-going to
their labs and trying to understand a science that I am not trained
in. In the early 1980s, it was common for samples to be shared and
for people to call each other up and say, "Do you have a pedigree
for this? Can I have some DNA on that? I hear Finland has a few
interesting families," and so on. That era of collaboration and
sharing in basic research is coming to a rapid end, and this is not
unique to the U.S. The demise of the collaboration era is
4. Schnieke I. Wilmut et al., Viable Offspring Derived from Fetal and
Adult Mammalian Cells, Nature, Feb. 1997, at 810; Keith H. Campbell et al.,
Cloning: Eight Years after Dolly, Reproduction in Domestic Animals, Aug.
2005, at 256.
5" United Nations Declaration on Human Cloning, G.A. Res. 59/280, U.N.
GAOR, 59th Sess., U.N. Doc. A/RES/59/280 (Mar. 23, 2005).
6" See, e.g., World Health Organization, Cloning in Human Health, Report
by the Secretariat, 52d Assembly (Apr. 1999).
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attributable to the alliance between academia and industry that is
promoted by the universities and by governments who say that the
private sector should pull its own weight, and that the public sector
alone cannot shoulder the full costs of basic research.
This shift has led to perceived and actual conflicts of interest,
and we find "gag clauses" in the contracts that are drawn up for
researchers working in labs dealing with health issues and looking
for therapies for humans. These clauses say things like, "You
cannot publish, you cannot talk at a meeting, you cannot submit an
abstract, you cannot do anything in the public domain until you
have the approval of a commercial sponsor." 7 This has caused
many student researchers under the level of post-doc to opt-out of
working in labs to ensure that they will still have the freedom to
get their thesis through without being slowed down by this kind of
process. This situation is not as dim and dismal as I make it out to
be; it is the reality, if you like, of a new kind of funding.
Nevertheless, this new reality demands more transparency and
perhaps calls for rules that ensure freedom of basic research while
promoting research support.
Patents and proprietary interests under commercialization have
received tremendous world attention. Access to AIDS drug
treatments, the imposition of patent norms on developing
countries, and tensions between the holders of proprietary interests
in the breast cancer gene test and universal health care systems are
the subject of worldwide debate. 8 There are countries that have
said that they do not think the gene in any form should be
patentable, obviously showing a misunderstanding of the patent
system, as well as the gene, in terms of what is actually. going on.
And there are researchers who have patented their innovations, and
who have actually done it purposely in order to put the knowledge
into the public domain so it could be used, and have ensured very
broad licensing arrangements to make sure patent interests do not
7. Genevieve Cardinal & Bartha Maria Knoppers, Lorsqu'en Recherchg
Ggngtique, Financement Privg ne Rime Plus Avec Santg, in Les Pratiques de
Recherchd Biomrdicale Visitres par la Biorthique (Chrisitan Herv6 et al. eds.,
2003).
8. Yann Joly, Acc~s Aux M~dicaments: Le Systtme International des
Brevets Empehera-t-il les Pays du Tiers Monde de Bdneficier des Avantages de
la Pharmacoggnomique, Les Cahiers de Proprit6 Intellectuelle (2003).
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adversely affect the health care system. In Europe, there is still
opposition to the breast cancer gene test put out by Myriad for
many reasons. 9 The current worry is that the debate we have had
over patents through the last decade will be repeated in an even
broader, potentially endless debate over the legitimacy of
copyright in genomic databases.
To conclude then on these four phenomena and on the subject
of commercialization, the one issue that has not been squarely
faced in Europe, Japan, and Canada is the impact of the large
number of patents issued, each with exclusive rights and licenses,
on a universal health care system. Now, in a universal health care
system such as Canada's, to give you an example, when the
BRCA1 and BRCA2 genes were patented by Myriad, the exclusive
license was given to one company in Canada. Of course, that
allowed one company to set the price at a rate they desired. The
resulting inequitable access by women with breast cancer across
Canada was a first for the Canadian universal health care system.10
Some supported offering the test to patients on a case-by-case
basis, each to be approved by the Ministry of Health. Others said,
"No, we have a test that we're going to use that is not as good but
at least everyone will get access to it." And others said, "No,
we're going to contest the patent."'"1 Variations of this scenario are
taking place in many other countries with universal health care
systems.
Keeping these four phenomena in mind, let us move to how
these perceptions, social representations if you like, of human
genetics and advances therein will affect the three topics we will
be looking at tomorrow and the next day. Such consideration was
9. Sabine Steimle, Critics Question BRCA2 Patent Decision in Europe,
Journal of the Cancer Institute, Sept. 21, 2005, at 18.
10. Laura Eggertson, Ontario Defied US. Firm's Genetic Patent, Continues
Cancer Screening, Canadian Medical Association Journal, Feb. 19, 2002, at 166.
11. T. Caulfield et al., Genetic Technologies, Health Care Policy and the
Patent Bargain, Clinical Genetics, Jan. 2003, at 15; Richard Gold et al., Gene
Patents and the Standard of Care, Canadian Medical Association Journal, Aug.
6, 2002, at 167; Jinisi Paradise, European Opposition to Exclusive Control over
Predictive Breast Cancer Testing and the Inherent Implications for United
States Patent Law and Public Policy: A Case Study of the Myriad Genetics'
BRCA Patent Controversy, 59 Food and Drug L.J. 133 (2004).
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directly integrated into the Human Genome Project ("HGP") when
it put a percentage of its budget aside to contemplate ethical, legal,
and social implications under worldviews.12
In other words, HGP planned that ethics would be part of the
advances in genetic research. Therefore, before looking
specifically at population health, pharmacogenomics, and the
Haplotype Map, we have to ask ourselves whether these endeavors
fully integrate and conceptually constitute a solid triangle depicting
the advancement of science or, rather, a more surreal painting
depicting Darwin, Dali, and science. In other words, we must ask
ourselves whether these three very important endeavors will be
able to contribute to the advancement of science in a tangible,
meaningful manner.
Currently, population health has three sources of policies that
will protect human subjects, protect or advance population health,
or obstruct it. The first is that of personal data legislation. A lot of
personal data legislation originated in the 1980s from fears of state
surveillance, the creation and use of information banks for
commercial marketing, and access to personal financial data by
credit card companies and other entities. So there are very strong
personal privacy concerns surrounding the elaboration of these
particular laws.
Consider that, at the same time these concerns arose, we also
had the emergence of forensic banks, including forensic databanks
on violent criminals and recidivists.1 3  Here, there are socially
carved exceptions to personal data legislation to promote public
security and public safety interests. But these new personal data
laws lost a traditional exception, which has existed since the 1950s,
for public health concerns. No longer was there an opportunity for
the state to intervene on behalf of the population and legitimately
12. The Human Genome Organisation, http://www.hugo-intemational
.org/committeeethics.htm.
13. The Federal Bureau of Investigation in the United States operates the
Combined DNA Index System, which is available at http://
www.fbi.gov/hq/lab/codis/indexl.htm; The Royal Canadian Mounted Police
operates the National DNA Databank, which is available at http:/I
www.rcmp.ca/security/index e.htm. See also Donald Crosby, Protection of
Genetic Information: An International Comparison (2000).
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access personal data. These provisions were reduced, except in the
forensic or national security areas.
At the same time, the protection of medical records per se
increased with the popularity of the notion that the confidentiality
of such data is important and that genetic data should also be
protected.14  But should genetic information be protected under
personal data legislation, under medical data legislation, or should
it have its own sphere of protection carved to fit this kind of data?
Well, I have argued that the best approach would be to increase
protection of medical data and integrate genetic data therein so as
to avoid the deterministic approach and avoid the kind of
discrimination that comes when you think genetic data somehow is
different-that it is not part of the normal human condition.
Medical data, and the protection thereof, has also been
influenced by the codes of ethics that have emerged since the
Nuremberg Code of 1947. These codes, specifically aimed at
protecting research subjects, have grown and multiplied over the
years. I could easily do a good Ph.D. study comparing these codes
and their sometime contradictory statements which, perhaps, is
good because of cultural differences. But one common thread runs
through all of the ethical codes involving medical and biomedical
research, and that is the protection of the individual, the autonomy
of the individual. 15
So, pulling together personal data legislation, medical
protection, and the principle of autonomy, one must ask herself,
"How can we still do population health research? How can we
build a philosophy, if you like, of populations?" Maybe genetics
will get us there because genetics transcends the individual. It is
necessarily familial; we are going to have to rework those codes
with an eye towards families. Genetics is also communities and, in
14. See generally Genetic Secrets: Protecting Privacy and Confidentiality
in the Genetic Era (Mark A. Rothstein ed., 1997); Genetic Ethics: Do the Ends
Justify the Genes? (John F. Kilner et al. eds., 1997).
15. See, e.g., World Health Organization, Genetic Databases: Assessing the
Benefits and the Impact on Human & Patient Rights (2003); World Medical
Association, Declaration of Helsinki (2002), available at http://www
.wma.net/e/policy/b3.htm; U.N. Education, Scientific, & Cultural Organization
[UNESCO], International Declaration on Human Genetic Data, Art. l(a) (Oct.
16, 2003).
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some regions, it is ethnic groups. We have known this for quite a
while, but we have not really done much applied medicine with
that knowledge, except through specialized screening programs.
And now, as we will see starting tomorrow, genetics is
encompassing whole regions and countries through establishment
of biobanks; populations are learning to think of their genes and
their records as resources for research.
Potential collective benefits rather than immediate, individual
benefits are driving this trend. It is not as if participants were in a
clinical drug trial for cancer, obesity, or hypertension. How do we
change the mindset of people to participate in these necessarily
longitudinal studies? The problem is that, even if we get citizens
to participate, and even if things go well, the language used to
identify the samples-to take but two examples: coded,
anonymized, de-identified schemes under the Health Insurance
Portability and Accountability Act ("HIPAA"), 16 and double-
coded, reversibly anonymized schemes in the United Kingdom
biobanklT--will make it impossible to collaborate and share these
samples on an international level. The taxonomy or the
nomenclature, whatever you want to call it, is the vocabulary that
could thwart necessary international collaboration and sharing.' 
8
What about pharmacogenomics? The alchemist during the
Middle Ages had two goals, one was to find immortality and the
other was to turn gross metals into gold. Well, some have likened
this new era of pharmacogenomics and individual life medicine,
molecular medicine, and so on to a new era of alchemy. But in
2003, the American Journal of Pharmacogenomics, in an article
entitled Pharmacogenomics and Individualized Drug Therapy:
High Expectations and Disappointing Achievements concluded,
"For the next five years or longer, we do not expect that tests based
on these approaches will become available to the practicing
16. Health Insurance Portability and Accountability Act of 1996, Pub. L.
No. 104-91, 110 Stat. 1936.
17. The Wellcome Trust, Medical Research Council and Department of
Health, U.K. Biobank Ethics and Governance Framework, http://www.
ukbiobank.ac.uk/docs/egf-comment-version.doc.
18. Bartha Maria Knoppers & Madelaine Saginur, The Babel of Genetic
Data Terminology, Nature Biotechnology, Aug. 1, 2005, at 925.
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clinician."' 9 Now, I do not want to be a prophet of doom. I think
what they mean is that pharmacogenomics is going to stay largely
in the research sphere for the foreseeable future. In fact, some
would argue that there are certain dangers in disease stratification
and patient stratification. I do have some positive, immediate
hopes, however, for pharmacogenomics. At a minimum, it will
probably be used in terms of genotyping to exclude people from
Phase 1 trials, people who would be at risk for adverse effects such
as death from toxicity and so on. So pharmacogenomic probably
will make a meaningful debut in clinical trials rather than clinical
care, and in terms of ensuring safety and exclusion rather than
inclusion and treatment.
Now, a few words to place the Haplotype Map into the context
of the four phenomena. Here we are, rather than doing candidate
genes and dealing with families with rare, inherited conditions, we
are looking at assembling a resource, a research tool, that will
allow us to build ancestral blocks and a better understanding of
genetic variation and the role that genetic variation plays in the
expression of genetic diseases. So it is not really a genetic map, it
is a genomics map. You will hear much during this conference
about the implications of shifting from traditional population
health to haplotype mapping. For example, the haplotype mapping
people have their hands full because people say, "It's okay, you're
not identifying people; you are using anonymized samples." But
these samples are taken from populations, such as the Yorubans in
Nigeria, the Han Chinese in China, the Japanese, and the Mormon
population of Utah. So people will be profiled, albeit collectively.
The more we know, the more we will associate risks and diseases
with the Chinese, the Yorubans, and so forth. And so we will
attribute, if you like, genetic characteristics based on such origins;
we will be labelling.
What if we find out that people who thought they were from
one ethnic origin, people who have built countries and established
land ownership and cultural history tied to ancestral beliefs, who
have relied on their beliefs about their identity when in fact these
19. D.W. Nebert et al., Pharmacogenomics and "Individualized Drug
Therapy": High Expectations and Disappointing Achievements, 3 Am. J.
Pharmacogenomics 361, 370 (2003).
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beliefs have no biological basis and, in fact, the biology runs
against their beliefs? The social-political constructs that we have
built up over time in history might prove to be unfounded,
biologically speaking. So these are some of the challenges facing
this very important effort, and one that I think, in the long run, will
serve not only as a research tool, but also as a resource for the
validation of other genetic tests.
In conclusion, we are talking about new policies, legislation,
regulations, guidelines, or a combination thereof in response to the
genomics revolution. We must consider our options and chart an
approach. I talked about genetics-specific legislation, and the
dangers of adopting genetics-specific laws that usually prove to be
inadequate. When Dolly was born, several countries enacted
legislation to ban cloning but the science was so specifically
described in the definition sections that the technique used in Dolly
was not covered. 20  So there are specific laws, there are self-
regulatory codes and codes of conduct, and guidelines.2 1 There is
also the free-market approach.22 Finally, there is the approach that
I favor, which is that of human rights.
I would argue that privacy, liberty, security, integrity, and,
perhaps, new human rights will emerge. How we interpret human
rights can incorporate understandings of the new biology, of the
new genomics. We should adapt human rights to frame these
technologies. If we increase the protection of medical records, if
we are more transparent about commercial partnerships, if we
increase their accountability, if we have more oversight by
accredited, knowledgeable IRBs (independent review boards),
incidentally, a real challenge in the population domain, if we move
away from "What's in it for me"--the notion of personal benefit
above all-and towards more of a citizen approach, if we stop
equating tissues with humans and genes with persons, then I think
we might have some possibility in the next decade of having a
20. George J. Annas et al., Protecting the Endangered Human: Toward an
International Treaty Prohibiting Cloning and Inheritable Alterations, 28 Am.
J.L. & Med. 151 (2002).
21. Bartha Maria Knoppers, Reflection: The Challenge of Biotechnology
and Public Policy, 45 McGill L.J. 559 (2000).
22. Id.
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more international approach, more harmonization, and, thus,
collaboration.
One of the first slides shown today mentioned the word
"epigenesis," and if you look at physics, you see an epigenetic
approach-a complex systems approach that brings in all the
interactive elements. We are really in a complex system of
networks. These intersecting domains will allow a systems
approach if we can handle the complexity and stay away from the
polarization, the black and white, the polemic, and the rhetoric. If
we arrive at this approach, I think we can handle the future that
these three promising areas bring. One thing for sure is that if we
tone down the rhetoric and the hype, and if we truly believe that
these public endeavors are equally important to any other
individual intervention, we may restore public trust and, I hope,
increase public participation in these population endeavors.

